1. Introduction {#sec1-cancers-10-00298}
===============

Rare diseases are defined as disorders that affect fewer than 200,000 people in the United States \[[@B1-cancers-10-00298]\]. Although these disorders can often be chronic, debilitating, and life-limiting illnesses there are few effective therapies for these diseases ([Figure 1](#cancers-10-00298-f001){ref-type="fig"}) \[[@B1-cancers-10-00298]\]. This is largely because pharmaceutical industries are unable to recover the cost associated with the R&D and marketing of such drugs \[[@B1-cancers-10-00298]\]. The FDA Office of Orphan Products Development (OOPD) focuses on the development of drugs and products for rare diseases ([Figure 1](#cancers-10-00298-f001){ref-type="fig"}). Interestingly, many rare diseases are caused by the altered function of DNA damage response (DDR) genes causing genome instability---a hallmark of cancer. Since DDR genes are crucial for maintaining genome stability, mutations in these genes may have downstream cancer burden associated with them. Hence, understanding the biology of rare DNA repair diseases can help identify novel cancer therapies.

The DDR network includes several DNA repair pathways, which depending on the type of DNA lesion is employed by the cell to orchestrate repair \[[@B2-cancers-10-00298],[@B3-cancers-10-00298]\]. There are several DNA lesions that can affect a cell: (A) single-stranded breaks, (B) base modifications (e.g., methylation, oxidation), (C) base mismatch (e.g., insertions, deletions, translocations), (D) incorporation of bulky adducts during replication (covalent attachment of aryl groups to the DNA), (E) incorporation of abasic sites (where a base is missing from the DNA), (F) interstrand and intrastrand covalent crosslinks, and (G) double-stranded breaks. Due to space limitations, in the following section we briefly discuss the repair of single-strand and double-strand DNA breaks.

1.1. Repair of Single-Strand DNA Breaks (SSBs) {#sec1dot1-cancers-10-00298}
----------------------------------------------

SSBs, as the name suggests, afflicts one strand of the DNA double helix and is repaired by one of three pathways; base excision repair (BER), nucleotide excision repair (NER) and mismatch repair (MMR) \[[@B4-cancers-10-00298]\]. BER, NER, and MMR are vital cellular pathways essential for the maintenance of genome integrity and cell survival (reviewed in \[[@B5-cancers-10-00298],[@B6-cancers-10-00298],[@B7-cancers-10-00298],[@B8-cancers-10-00298]\]). Briefly, BER has evolved to repair endogenous DNA damage that can lead to modifications in the DNA bases such as alkylation, oxidation and deamination \[[@B5-cancers-10-00298]\]. NER is distinguished from BER due to its versatility of sensing structural distortions in the double helix rather than specific base modifications \[[@B9-cancers-10-00298],[@B10-cancers-10-00298]\]. "Bulky" lesions generated by UV radiation such as cyclobutane pyrimidine dimers (CPDs) and 6,4-photoproducts (6-4PPs) generate structural distortion in the DNA that obstruct progression of transcription and replication machineries that can lead to genome instability if left unrepaired \[[@B11-cancers-10-00298]\]. MMR is involved in postreplication repair (PRR) and corrects DNA mismatches generated during DNA replication and recombination that escapes the proofreading function of DNA polymerases and can become permanent in dividing cells if left unrepaired. MMR thereby prevents both mutagenesis in the short term and oncogenesis in the long term \[[@B12-cancers-10-00298],[@B13-cancers-10-00298]\].

1.2. Repair of Double-Strand DNA Breaks (DSBR) {#sec1dot2-cancers-10-00298}
----------------------------------------------

The two major DSBR pathways employed by the cell for the repair of broken DNA ends primarily differ in the use of a homologous DNA template for repair. Homologous recombination (HR) is an error-free, template-dependent pathway that uses DNA molecules of "identical or nearly identical nucleotide sequences" as template to copy the information across the double-strand break (DSB) ([Figure 2](#cancers-10-00298-f002){ref-type="fig"}A) \[[@B14-cancers-10-00298]\]. Non-homologous end-joining (NHEJ), does not depend upon sequence homology to recover the lost genetic information at the site of the DNA break and is a mutagenic, error-prone mechanism of DNA repair \[[@B11-cancers-10-00298]\]. A second NHEJ concomitant pathway often referred to as alternative-NHEJ (Alt-NHEJ)/Microhomology-mediated end-joining (MMEJ) differs from NHEJ most significantly in that it uses shorter homology overhangs (5--25 base pair (bp)) on the ends of the double-strand breaks during the alignment of the broken ends before religating them \[[@B15-cancers-10-00298]\]. Though both these pathways are highly conserved throughout evolution, HR appears to be the predominant mechanism of DSBR during embryogenesis (and S/G2 phases of cell cycle), whereas NHEJ is a major pathway for repair in post-natal life and in the G0/G1 phase of the cell cycle \[[@B16-cancers-10-00298]\].

In this review, we highlight how insights from understanding the biology of rare genetic diseases with defects in DNA damage response and repair can be translated to the clinic for cancer therapy. We discuss four diseases---Werner syndrome (WS), Bloom syndrome (BS), Ataxia telangiectasia (AT) and Fanconi Anemia (FA). We highlight the latest research in the development of small molecule inhibitors for these DNA damage repair enzymes that are being used in the clinic either as single agent or in combination with radio- and/or chemotherapy to exploit defects in DNA damage repair pathways in cancer cells.

2. Leveraging Insights from the Biology of Rare Genetic Diseases for Targeted Cancer Therapy {#sec2-cancers-10-00298}
============================================================================================

Geneticist Calvin Bridges first described synthetic lethality as a genetic interaction in which deficiency in a pair of genes results in cell death, while the disruption of either gene is viable \[[@B17-cancers-10-00298]\]. The key impediment to exploiting synthetic lethality in cancer therapy is the identification of robust synthetic lethal genetic interactions \[[@B6-cancers-10-00298]\]. What makes DNA repair genes attractive targets for cancer therapy using the synthetic lethality approach is; (1) many DNA repair genes have synthetic lethal relationships with oncogenes and tumor suppressor genes, (2) many repair genes and repair pathways are upregulated in tumors giving rise to a distinct genetic profile that can be exploited for targeted killing of cancer cells, (3) several cancer cells are dependent on DNA repair pathways for survival in response to genotoxin stress (e.g., radio/chemotherapy) \[[@B6-cancers-10-00298],[@B18-cancers-10-00298],[@B19-cancers-10-00298],[@B20-cancers-10-00298],[@B21-cancers-10-00298],[@B22-cancers-10-00298],[@B23-cancers-10-00298],[@B24-cancers-10-00298]\]. In fact, in recent years, the success of poly(ADP ribose) polymerase inhibitors (PARPi): small molecules that inhibit the molecular and cellular function of PARP-1 and in doing so exploits the synthetic lethal relationship between PARP and BRCA1 or BRCA2 in BRCA1/2-null (ovarian or breast) tumors in response to platinum-based chemotherapy has made chemically induced synthetic lethality more mainstream in the development of new generation anti-cancer drugs \[[@B25-cancers-10-00298],[@B26-cancers-10-00298]\].

PARP-1 is a nuclear enzyme that senses and binds to single-stranded DNA breaks and catalyzes the formation of PARP polymers by a process known as poly(ADP-ribosyl)ation (PARylation) \[[@B27-cancers-10-00298]\]. PARP-1 uses the PAR chains to serve as a docking platform for the recruitment of DNA repair factors to the site of the break; in particular, PARP-1 recruits the BER core-complex proteins such as XRCC1, Polβ and DNA ligase III to orchestrate repair \[[@B27-cancers-10-00298],[@B28-cancers-10-00298]\]. PARP-1 inhibition leads to an accumulation of SSBs, which if left unrepaired lead to collapse replication forks that are essentially DSBs and rely on HR for replication restart and repair \[[@B29-cancers-10-00298]\]. *BRCA1* and *BRCA2* are tumor suppressor genes that are also key HR repair protein \[[@B29-cancers-10-00298]\]. Due to their synthetic lethal relationship, in HR-defective BRCA1/2-mutant cells, that is, cancer cells, chemical inhibition of PARP-1 is selectively toxic in combination with conventional chemotherapy \[[@B29-cancers-10-00298]\].

Applying the principle of chemically induced synthetic lethality to identify targets for cancer therapy has immense potential and relies on the identification of inhibitors that can selectively modulate DNA repair proteins that are either directly or indirectly involved in carcinogenesis. In the following section, we discuss four DNA repair genes/gene networks: Werner helicase, Bloom helicase, ATM kinase and Fanconi Anemia proteins and how pharmacologically inhibiting these gene products in combination with a cancer driver mutation is synthetically lethal and can be exploited for developing orphan drugs.

3. Werner Syndrome {#sec3-cancers-10-00298}
==================

WS is an adult-onset, autosomal-recessive, representative segmental progeroid syndrome \[[@B30-cancers-10-00298]\]. Dr. Otto Werner at the Royal Albrecht University of Kiel first described WS in 1904 \[[@B31-cancers-10-00298]\]. The clinical phenotypes of WS include an early onset of aging symptoms such as bilateral cataracts, abnormal glucose and lipid metabolism, hypogonadism, atherosclerosis, diabetes, skin ulcers, osteoporosis, and other age-related disorders \[[@B32-cancers-10-00298],[@B33-cancers-10-00298]\]. Individuals with WS show no observable phenotype in their first decade. Generally, the first sign of WS is a lack of the pubertal growth spurt during teenage years \[[@B34-cancers-10-00298]\]. WS is a rare genetic disorder with an estimated global incidence ranging between 1 in 1,000,000 and 1 in 10,000,000 births; however, demographically the incidence is higher in Japan at 1 in 100,000 births \[[@B35-cancers-10-00298]\]. WS is caused by a mutation in the WRN gene that encodes a 180 kDa RecQ type DNA/RNA helicase that possesses both helicase and exonuclease activities ([Figure 2](#cancers-10-00298-f002){ref-type="fig"}A) \[[@B36-cancers-10-00298]\]. WS is associated with abnormalities in many DNA metabolic pathways such as DNA repair, replication, and telomere maintenance \[[@B36-cancers-10-00298]\].

3.1. Werner Helicase in Non-Homologous End-Joining and Base Excision Repair {#sec3dot1-cancers-10-00298}
---------------------------------------------------------------------------

WRN plays a regulatory role in pathway choice during DSBR by stimulating NHEJ and inhibiting MMEJ \[[@B37-cancers-10-00298]\]. DNA-PKcs and its regulatory subunit, Ku70/80, initiates NHEJ repair in response to DNA damage that results in the formation of DSBs \[[@B38-cancers-10-00298]\]. The Ku70/80 complex has been shown to physically interact with WRN and enhance its exonuclease activity without affecting its helicase activity \[[@B39-cancers-10-00298]\]. The processing of the broken DNA ends by WRN generates substrates suitable for ligation by XRCC4 and ligaseIV \[[@B38-cancers-10-00298]\].

WRN knockdown cells show sensitivity to DNA damaging agents (mitomycin C, camptothecin, and hydrogen peroxide) and reduced BER activity \[[@B40-cancers-10-00298],[@B41-cancers-10-00298],[@B42-cancers-10-00298]\]. BER proceeds either via short-patch (SP-BER), in which one single nucleotide, or via long-patch (LP-BER), where greater than one nucleotide is incorporated during the repair process \[[@B43-cancers-10-00298]\]. WRN has been shown to physically and functionally interact with proteins involved in both SP-BER and LP-BER. Notably, the strand displacement activity of DNA Polymerase β (Pol β), involved in both SP-BER and LP-BER is stimulated by WRN helicase activity \[[@B44-cancers-10-00298],[@B45-cancers-10-00298],[@B46-cancers-10-00298]\]. WRN helicase activity cooperates with its (1) proofreading activity to assist Pol β during LP-BER and (2) exonuclease activity to process BER intermediates with 3′-mismatches \[[@B41-cancers-10-00298],[@B47-cancers-10-00298]\]. WRN also interacts with other enzymes involved in SP-BER and LP-BER, including apurinic/apyrimidinic endonuclease 1 (APE1), flap endonuclease 1 (FEN-1) and poly(ADP-ribose) polymerase 1 (PARP-1), among others \[[@B48-cancers-10-00298],[@B49-cancers-10-00298],[@B50-cancers-10-00298]\].

3.2. Small Molecule Inhibitors and Werner Helicase {#sec3dot2-cancers-10-00298}
--------------------------------------------------

Modulation of DNA repair proteins by small molecule inhibitors as targets for anticancer therapy has attracted great interest in recent years. The WRN helicase is one of these DNA repair factors. Two small molecule inhibitors from the National Cancer Institute (NCI) Diversity Set, NSC 19630 and NSC 617145 have been identified as pharmacological inhibitors of WRN helicase activity \[[@B51-cancers-10-00298],[@B52-cancers-10-00298]\]. NSC 19630 \[1-(propox-ymethyl)-maleimide\] has been reported to inhibit growth of cell lines in various cancers with a notably strong representation in leukemia and renal cancer \[[@B52-cancers-10-00298]\]. NSC 617145 \[1,1′-(2,2-Dimethyl-1,3-propanediyl)bis\[3,4-dichloro-1H-pyrrole-2,5-dione\] is reported to be a candidate for chemically inducing synthetic lethality in Fanconi Anemia-deficient tumors harboring autosomal recessive mutations in either the FA group A (FANCA) or group D (FANCD2) genes \[[@B51-cancers-10-00298]\]. FA-A and FA-D2 cells show hypersensitivity to low concentrations of MMC when co-treated with NSC 617145. This is because NSC 617145 acts synergistically with MMC and exacerbates MMC-induced DNA damage that accumulates in the absence of a functionally intact FA pathway. NSC 19630 and NSC 617145 are both attractive drugs for developing improved anticancer treatment regimens.

4. Bloom Syndrome {#sec4-cancers-10-00298}
=================

BS is an autosomal recessive chromosomal instability syndrome \[[@B53-cancers-10-00298]\]. The clinical phenotypes of BS include prenatal and postnatal growth retardation, sunlight sensitivity, immune deficiency, fertility defects and a predisposition to the development of cancer, most commonly leukemia and lymphoma \[[@B54-cancers-10-00298],[@B55-cancers-10-00298]\]. BS is a rare genetic disorder with fewer than 300 cases reported. However, epidemiologically, one-third of people with the disease are of Eastern European Jewish (Ashkenazi) decent and a disease prevalence of approximately 1:48,000 \[[@B53-cancers-10-00298],[@B56-cancers-10-00298],[@B57-cancers-10-00298]\]. BS is due to mutations of the *BLM* gene (15q26.1), which encodes the BLM DNA helicase. BLM is a member of the conserved RecQ helicase family, an enzyme involved in maintenance of genomic integrity ([Figure 2](#cancers-10-00298-f002){ref-type="fig"}A) \[[@B58-cancers-10-00298],[@B59-cancers-10-00298]\]. Due to its helicase activity, BLM, like WRN, functions to facilitate several metabolic processes that involve unwinding the DNA helix including DNA replication, RNA transcription, and DNA repair \[[@B60-cancers-10-00298]\].

4.1. Bloom Helicase and Homologous Recombination {#sec4dot1-cancers-10-00298}
------------------------------------------------

BLM protein displays a DNA-dependent ATPase activity and 3′--5′ DNA helicase activity that can unwind a variety of DNA substrates that arise during HR-mediated DNA repair. Accurate processing of these DNA intermediates is crucial for the maintenance of chromosomal stability and genomic integrity \[[@B61-cancers-10-00298]\]. BLM, along with its conserved partner enzymes, including topoisomerase IIIα, RMI1 and 2 can also branch migrate recombination intermediates like DNA displacement loops (D-loop) and Holliday junctions (HJs) and channel these DNA molecules away from pathways leading to crossover products ([Figure 2](#cancers-10-00298-f002){ref-type="fig"}A) \[[@B62-cancers-10-00298],[@B63-cancers-10-00298],[@B64-cancers-10-00298],[@B65-cancers-10-00298],[@B66-cancers-10-00298],[@B67-cancers-10-00298]\]. In the absence of BLM, HR is still functional albeit unregulated; this results in an increase in the number of sister chromatid exchanges (SCE) which arise by HR between sister chromatids during the S or G2 phases of the cell cycle that are characteristic of the syndrome \[[@B59-cancers-10-00298],[@B68-cancers-10-00298],[@B69-cancers-10-00298]\].

4.2. Small Molecule Inhibitors and Bloom Helicase {#sec4dot2-cancers-10-00298}
-------------------------------------------------

The compound, designated ML216, identified from a high-throughput screen of a chemical compound library and medicinal chemistry optimization, is a potent small molecule inhibitor of BLM \[[@B54-cancers-10-00298]\]. This inhibitor acts through competitive inhibition of the DNA binding activity of BLM \[[@B54-cancers-10-00298]\]. In cell-based assays, using cultured human fibroblasts; ML216 induces SCEs, elevated sensitivity to aphidicolin (an inhibitor of replicative DNA polymerases) and reduced proliferation \[[@B54-cancers-10-00298]\]. However, these phenotypes were not observed in otherwise isogenic, BLM-deficient cells \[[@B54-cancers-10-00298]\]. These observations warrant further studies for the potential development of a new class of chemotherapy drugs to treat tumors that rely on BLM for proliferation.

Cu/Zn superoxide dismutase 1 (SOD1) is a non-essential gene that acts as a regulator of antioxidant defense \[[@B70-cancers-10-00298]\]. Published reports suggest a synthetic lethal relationship between BLM and SOD1 in colorectal cancer (CRC) cell models \[[@B71-cancers-10-00298]\]. Using siRNA-based silencing, chemical inhibition of SOD1 by ammonium tetrathiomolybdate (ATTM) and Lung Cancer Screen-1 (LCS-1), the authors report the induction of selective killing within *BLM*-deficient cells \[[@B71-cancers-10-00298]\]. This data identifies SOD1 as a novel drug target in *BLM* CRC contexts.

5. Ataxia Telangiectasia {#sec5-cancers-10-00298}
========================

A-T is a rare, recessive genetic disorder that is primarily an immunodeficiency disease and affects a number of different organs in the body \[[@B72-cancers-10-00298]\]. A-T is characterized by dilated blood vessels (telangiectasia) and a loss of voluntary movement coordination that includes a gait abnormality (ataxia) \[[@B72-cancers-10-00298]\]. A-T is a rare genetic disorder with an estimated global incidence ranging between 1 out of 40,000 and 1 out of 100,000 births worldwide with no reported geographical or demographical epidemiology (data from NCI). A-T is due to mutations of the *ATM* gene, a member of the phosphatidyl inositol 3-kinase-like family of serine/threonine protein kinases (PIKKs) \[[@B73-cancers-10-00298],[@B74-cancers-10-00298]\]. The ATM gene is located on chromosome 11q 22--23, includes 66 exons, and encodes a 370 kDa serine/threonine protein kinase \[[@B75-cancers-10-00298]\]. ATM mediates checkpoint control by inducing cell cycle arrest at G1/S, S and G2/M phases in cells exposed to ionizing radiation (IR) and other agents that produce DSBs. In response to DNA damage, several proteins are phosphorylated at Ser/Thr-Glu motifs and additional sites in an ATM-dependent manner \[[@B76-cancers-10-00298],[@B77-cancers-10-00298],[@B78-cancers-10-00298],[@B79-cancers-10-00298]\]. ATM also exerts cell cycle delay, in part, by phosphorylation and activation of downstream effector kinases, like Checkpoint kinase 2 (Chk2), which, in turn, phosphorylates p53 and several other targets \[[@B80-cancers-10-00298],[@B81-cancers-10-00298]\].

5.1. ATM and Double-Strand Break Repair {#sec5dot1-cancers-10-00298}
---------------------------------------

In response to DSBs, Mre11-Rad50-Nbs1 (MRN) complex is one of the first factors recruited to the site ([Figure 2](#cancers-10-00298-f002){ref-type="fig"}A). Once recruited, MRN recruits ATM to the DNA lesion by binding to the C terminus of NBS1 and subsequently stimulates ATM kinase activity \[[@B82-cancers-10-00298],[@B83-cancers-10-00298],[@B84-cancers-10-00298],[@B85-cancers-10-00298]\]. Following the activation of ATM by broken DNA ends, ATM rapidly phosphorylates S139 in the C-terminal tail of histone variant H2AX to form γH2AX \[[@B86-cancers-10-00298]\]. The protein Mdc1 mediates the recruitment of ATM to the chromatin flanking the DSBs \[[@B87-cancers-10-00298]\]. Through its C-terminal tandem BRCT domains, Mdc1 directly binds to γH2AX and through its FHA domain Mdc1 interacts with ATM \[[@B87-cancers-10-00298],[@B88-cancers-10-00298],[@B89-cancers-10-00298],[@B90-cancers-10-00298]\]. In addition, Mdc1 recruits MRN to chromatin by an interaction with the FHA-BRCT region of NBS1, thereby stimulating the phosphorylation of ATM, which in turn promotes additional γH2AX formation along chromatin \[[@B91-cancers-10-00298],[@B92-cancers-10-00298],[@B93-cancers-10-00298]\]. The phosphorylation of H2AX by ATM around DSBs triggers the chromatin-based signaling cascade involving phosphorylation, ubiquitylation, SUMOylation, and other post-translational modifications to promote recruitment of DNA repair proteins like BRCA1 and 53BP1 to the damage site \[[@B94-cancers-10-00298],[@B95-cancers-10-00298],[@B96-cancers-10-00298],[@B97-cancers-10-00298],[@B98-cancers-10-00298],[@B99-cancers-10-00298],[@B100-cancers-10-00298],[@B101-cancers-10-00298],[@B102-cancers-10-00298],[@B103-cancers-10-00298],[@B104-cancers-10-00298],[@B105-cancers-10-00298],[@B106-cancers-10-00298],[@B107-cancers-10-00298]\].

ATM has roles both in NHEJ and HR. NHEJ requires several proteins such as ATM, the MRN complex, DNA-PKcs, and Artemis \[[@B108-cancers-10-00298]\]. ATM is required for the phosphorylation and activation of DNA-PKcs \[[@B109-cancers-10-00298]\]. ATM and DNA-PKcs are also essential for Artemis activation and recruitment to DNA ends \[[@B110-cancers-10-00298]\]. ATM promotes HR by phosphorylating and activating CtIP, a downstream effector molecule important for DSB end resection ([Figure 2](#cancers-10-00298-f002){ref-type="fig"}A). Presence of CtIP at the DNA lesion facilitates the recruitment of replication protein A (RPA) to initiate HR \[[@B111-cancers-10-00298],[@B112-cancers-10-00298],[@B113-cancers-10-00298]\]. Moreover, ATM-dependent phosphorylation of CtIP promotes the removal of Ku from single-ended DSBs and sets in motion Rad51-mediated strand invasion step of HR \[[@B114-cancers-10-00298]\].

5.2. Small Molecule Inhibitors and ATM-CHK2 Helicases {#sec5dot2-cancers-10-00298}
-----------------------------------------------------

Due to their central role in promoting DNA repair and facilitating the resistance of cancer cells to genotoxin treatment, the ATM-CHK2 kinases are excellent candidates for modulation by small molecules inhibitors for targeted cancer therapy. [Table 1](#cancers-10-00298-t001){ref-type="table"} summarizes a comprehensive list of small molecule inhibitors of ATM and CHK2 that are in preclinical or clinical development for cancer therapy being tested either as single agents or in combination with radio-and/or chemotherapy.

6. Fanconi Anemia {#sec6-cancers-10-00298}
=================

First described by the Swiss pediatrician Guido Fanconi, FA is a rare cancer-susceptibility syndrome caused by biallelic mutations in one of the 21 known complementation groups and is inherited as recessive autosomal or X-linked genetic disease \[[@B127-cancers-10-00298],[@B128-cancers-10-00298],[@B129-cancers-10-00298],[@B130-cancers-10-00298],[@B131-cancers-10-00298]\]. The clinical phenotypes of FA include developmental disorders and physical abnormalities, progressive aplastic anemia, chromosomal fragility, congenital abnormalities and susceptibility to cancer: particularly myeloid leukemia and solid tumors including squamous cell carcinomas of the head and neck, liver tumors, and gynecologic malignancies \[[@B129-cancers-10-00298],[@B132-cancers-10-00298],[@B133-cancers-10-00298],[@B134-cancers-10-00298],[@B135-cancers-10-00298]\]. The incidence rate of FA is estimated to be about 1 in 136,000 live births. This rare condition has a higher incidence among people of Ashkenazi Jewish descent, the Roma population of Spain, and black South Africans due to founder mutations \[[@B133-cancers-10-00298]\]. FA can result from mutations in at least 21 genes. These genes encode for proteins, which along with several associated genes, form a nuclear multiprotein network that orchestrates DNA repair in a common pathway called the FA pathway ([Figure 2](#cancers-10-00298-f002){ref-type="fig"}B) \[[@B136-cancers-10-00298],[@B137-cancers-10-00298],[@B138-cancers-10-00298],[@B139-cancers-10-00298],[@B140-cancers-10-00298],[@B141-cancers-10-00298],[@B142-cancers-10-00298],[@B143-cancers-10-00298],[@B144-cancers-10-00298],[@B145-cancers-10-00298],[@B146-cancers-10-00298],[@B147-cancers-10-00298],[@B148-cancers-10-00298],[@B149-cancers-10-00298],[@B150-cancers-10-00298],[@B151-cancers-10-00298]\].

6.1. Fanconi Anemia Proteins and DNA Interstrand Crosslink Repair {#sec6dot1-cancers-10-00298}
-----------------------------------------------------------------

DNA interstrand crosslinks (ICLs) are toxic lesions that block replication and transcription by inhibiting the translocation of enzymes on the replication fork by covalently linking strands of the double helix leading to genome instability \[[@B136-cancers-10-00298]\]. There are two major pathways for the repair of ICLs: (1) replication-independent ICL repair and (2) replication-dependent ICL repair \[[@B152-cancers-10-00298]\]. The replication-dependent repair of ICLs is dependent on FA-mediated HR repair ([Figure 2](#cancers-10-00298-f002){ref-type="fig"}B) \[[@B152-cancers-10-00298]\].

The FA proteins have been divided into three groups and they act in a sequential manner to promote ICL repair \[[@B136-cancers-10-00298]\]. Group I (also known as the core complex) protein FANCM, a helicase and DNA translocase together with accessory factors Fanconi anemia-associated protein 24 (FAAP24), FAAP 100 and the histone fold proteins MHF1 (FAAP16 or CENPS) and MHF2 (FAAP10 or CENPX) recognizes the ICL and recruits other Group I proteins also known as the core complex consisting of FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCT, and FAAP20 to the ICL site ([Figure 2](#cancers-10-00298-f002){ref-type="fig"}B) \[[@B153-cancers-10-00298]\]. Following recruitment to the ICL, two core complex components FANCL (the E3 ligase) and FANCT (ubiquitin E2 ligase) ubiquitinates downstream Group II proteins FANCD2--I (also known as the ID complex) ([Figure 2](#cancers-10-00298-f002){ref-type="fig"}B) \[[@B154-cancers-10-00298],[@B155-cancers-10-00298]\]. The recruitment of the ID complex to the ICL is mediated by UHRF1 (ubiquitin-like with PHD and RING finger domains 1) protein, involved in ICL sensing ([Figure 2](#cancers-10-00298-f002){ref-type="fig"}B) \[[@B156-cancers-10-00298]\]. Ubiquination of the FANCD2--I complex is essential for the recruitment of nucleases to the ICL for promoting nucleolytic incision flanking the crosslink, a phenomenon referred to as 'unhooking' of the ICL ([Figure 2](#cancers-10-00298-f002){ref-type="fig"}B) \[[@B157-cancers-10-00298]\]. FANCD2-Ub first recruits the nuclease scaffolding protein SLX4 (FANCP) to the ICL, which then promotes the recruitment of other structure-specific endonucleases like XPF-ERCC1, MUS81-EME1, FAN1, and SLX1 to the site of the ICL ([Figure 2](#cancers-10-00298-f002){ref-type="fig"}B) \[[@B158-cancers-10-00298],[@B159-cancers-10-00298],[@B160-cancers-10-00298],[@B161-cancers-10-00298],[@B162-cancers-10-00298]\]. Following the unhooking step, translesion DNA polymerases such as REV7 (FANCV), and polymerase η inserts a base opposite the unhooked lesion and polymerase ζ extends DNA synthesis from the misincorporated base to fill the ssDNA gaps resulting from ICL unhooking in order to complete replication ([Figure 2](#cancers-10-00298-f002){ref-type="fig"}B) \[[@B163-cancers-10-00298],[@B164-cancers-10-00298]\]. The ssDNA gaps are converted to dsDNA breaks by MUS81--EME1, which is subsequently repaired by HR ([Figure 2](#cancers-10-00298-f002){ref-type="fig"}B) \[[@B165-cancers-10-00298]\].

6.2. Small Molecule Inhibitors and Fanconi Anemia Proteins {#sec6dot2-cancers-10-00298}
----------------------------------------------------------

Chemotherapeutic drugs like cisplatin and its derivatives, carboplatin and oxaliplatin act by inhibiting DNA replication by forming ICLs that impede the progression of the replication fork \[[@B166-cancers-10-00298]\]. The crucial role played by FA proteins in the cellular resistance to ICLs makes them excellent targets for inhibition by small molecule inhibitors that may sensitize cancer cells to radio- and/or chemotherapy \[[@B166-cancers-10-00298]\]. [Table 2](#cancers-10-00298-t002){ref-type="table"} summarizes a list of small molecule inhibitors of FANCD2 ubiquitination and foci formation; a marker of FA pathway abrogation that are in preclinical or clinical development for cancer therapy.

7. Conclusions {#sec7-cancers-10-00298}
==============

Identifying target genes/enzymes, and understanding the mechanism(s) underlying the progression of rare cancers provides us with the opportunity to: (A) exploit the disease-causing gene as a therapeutic target, and (B) expand the repertoire of targets for orphan drug discovery and development. In recent years, the success of small-molecule inhibitors for cancer therapy over conventional chemotherapy has directed scientific interest in identifying targetable enzymes that can be successfully modulated to improve the efficacy of current drugs. As presented in this review, enzymes implicated in rare genetic disease have been excellent targets for such modulation by small-molecule inhibitors and exploiting vulnerabilities in cancer. It is important to note that this approach also has certain limitations. First, there is a very high failure rate while designing new drugs particularly in late stages of clinical trials and second, many small-molecule inhibitors have high rates of cell toxicity making them unusable in therapy. However, with the advancements in next-generation genome sequencing technologies, identification of reliable biomarkers and large-scale gene profiling methods, the possibility of developing new personalized drugs for cancer patients is on the horizon.
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![A schematic for DNA damage response and repair Werner, Bloom, ATM, and Fanconi Anemia proteins are members of the DNA damage response network. (**A**) Werner and Bloom helicases and ATM serine/threonine kinase are involved in DNA end processing after the double-strand break is formed. (**B**) Fanconi Anemia proteins are involved in DNA interstrand crosslink sensing and repair by homologous recombination.](cancers-10-00298-g002){#cancers-10-00298-f002}

cancers-10-00298-t001_Table 1

###### 

Small molecule inhibitors of ATM-CHK2 Kinases in preclinical or clinical development for cancer therapy.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Target          Molecule    Stage of Testing                                                                                                                               Tumor Type                                 Reference/\
                                                                                                                                                                                                                        ClinicalTrial.gov Identifier
  --------------- ----------- ---------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ ------------------------------
  **CHK1/CHK2**   AZD7762     Phase 1\                                                                                                                                       Solid Tumors                               NCT00413686
                              Administered as single intravenous unit and in combination with gemcitabine                                                                                                               

  **CHK1/CHK2**   CBP501      Phase 1\                                                                                                                                       Advanced Solid Tumors                      NCT03113188
                              Administered in combination with cisplatin/nivolumab                                                                                                                                      

  **CHK1/CHK2**   LY2606368   Phase 1\                                                                                                                                       Neoplasm Metastasis Colorectal Neoplasm\   NCT02124148
                              Administered in combination with cisplatin/cetuximab/pemetrexed/fluorouracil                                                                   Breast Cancer                              

  **CHK1/CHK2**   LY2606368   Phase 2\                                                                                                                                       Ovarian Cancer\                            NCT02203513
                              Single agent                                                                                                                                   Breast Cancer\                             
                                                                                                                                                                             Prostate Cancer                            

  **ATM/ATR**     CGK733      Preclinical testing using Chk1-deficient HBV-positive hepatocellular carcinoma cells                                                           Hepatocellular carcinoma                   \[[@B115-cancers-10-00298]\]

  **ATM**         CP466722    Preclinical testing using multiple cell lines in combination with infrared radiation (IR)                                                      Cervical cancer\                           \[[@B116-cancers-10-00298]\]
                                                                                                                                                                             Fibroblasts                                

  **ATM/ATR**     Caffeine    Preclinical testing as single agent using human cancer cells and non-transformed mouse fibroblast cell lines                                   Breast Cancer\                             \[[@B117-cancers-10-00298]\]
                                                                                                                                                                             Prostate cancer                            

  **ATM**         KU59403     Preclinical testing using p53 functional and dysfunctional models of human cancer in combination with camptothecin, doxorubicin or etoposide   Osteosarcoma                               \[[@B118-cancers-10-00298]\]

  **ATM**         KU55933     Preclinical testing using human mesenchymal stem cells in combination with IR                                                                  Mesenchymal stem cells                     \[[@B119-cancers-10-00298]\]

  **ATM**         KU55933     Preclinical testing using ATM-defective and normal human fibroblast cells in combination with doxorubicin                                      Fibroblast                                 \[[@B120-cancers-10-00298]\]

  **ATM**         KU-60019    Preclinical testing using human glioma cells in combination with IR                                                                            Glioma                                     \[[@B121-cancers-10-00298]\]

  **ATM**         KU-60019    Preclinical testing using non-invasive breast cancer cells in combination with doxorubicin                                                     Breast Cancer                              \[[@B122-cancers-10-00298]\]

  **CHK2**        PV1019      Preclinical testing using human tumor cell lines in combination with topotecan, camptothecin or radiation                                      Ovarian Carcinoma                          \[[@B123-cancers-10-00298]\]

  **CHK2**        CCT241533   Preclinical testing using human tumor cell lines in combination with PARP inhibitors                                                           Colon Cancer\                              \[[@B124-cancers-10-00298]\]
                                                                                                                                                                             Breast Cancer\                             
                                                                                                                                                                             Glioblastoma\                              
                                                                                                                                                                             Osteosarcoma\                              
                                                                                                                                                                             Lung Cancer\                               
                                                                                                                                                                             Cervical Cancer                            

  **CHK1/CHK2**   XL-844      Preclinical testing using HT-29 cell line\                                                                                                     Colon Cancer                               \[[@B125-cancers-10-00298]\]
                              in combination with IR                                                                                                                                                                    

  **CHK1/CHK2**   XL-844      Preclinical testing using multiple cell lines in combination with gemcitabine                                                                  Pancreatic Cancer\                         \[[@B126-cancers-10-00298]\]
                                                                                                                                                                             Cervical Cancer\                           
                                                                                                                                                                             Ovarian Cancer                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

cancers-10-00298-t002_Table 2

###### 

Small molecule inhibitors of FANCD2 mono-ubiquitination in preclinical or clinical development for cancer therapy.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Target               Molecule         Stage of Testing                                                                         Tumor Type                                                                 Reference/\
                                                                                                                                                                                                            ClinicalTrial.gov Identifier
  -------------------- ---------------- ---------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ------------------------------
  **26S proteasome**   Bortezomib       Phase 3\                                                                                 Relapsed or Refractory Multiple Myeloma                                    NCT03234972
                                        Administered in combination with Daratumumab/bortezomib/dexamethasone                                                                                               

  **26S proteasome**   Bortezomib       Phase 3\                                                                                 Amyloidosis                                                                NCT03201965
                                        Administered in combination with daratumumab/cyclophosphamide bortezomib/dexamethasone                                                                              

  **26S proteasome**   Bortezomib       Phase 2\                                                                                 Multiple Myeloma                                                           NCT00153920
                                        As single agent                                                                                                                                                     

  **26S proteasome**   Bortezomib       Phase 2\                                                                                 Multiple Myeloma\                                                          NCT00075881
                                        As single agent                                                                          Stage I, II, and III                                                       

  **26S proteasome**   Bortezomib       Phase 2\                                                                                 Primary Peritoneal Cavity Cancer and Recurrent Ovarian Epithelial Cancer   NCT00023712
                                        As single agent                                                                                                                                                     

  **26S proteasome**   Bortezomib       Phase 2\                                                                                 Acute Lymphoblastic Leukemia                                               NCT02553460
                                        Administered in combination with bortezomib/vorinostat                                                                                                              

  **FANCF**            Curcumin         Preclinical testing using cell lines in combination with cisplatin                       Ovarian and Breast Cancer                                                  \[[@B167-cancers-10-00298]\]

  **FANCS**            Phenylbutyrate   Preclinical testing using cell lines in combination with cisplatin                       Head and Neck Cancer                                                       \[[@B168-cancers-10-00298]\]

  **USP1**             GW7647           Preclinical testing using cell lines in combination with cisplatin                       Non-small-cell Lung Cancer                                                 \[[@B169-cancers-10-00298]\]

  **USP1**             Pimozide         Preclinical testing using cell lines in combination with cisplatin                       Non-small-cell Lung Cancer                                                 \[[@B169-cancers-10-00298]\]

  **USP1-UAF1**        ML323            Preclinical testing using cell lines in combination with cisplatin                       Non-small-cell Lung Cancer and Osteosarcoma                                \[[@B170-cancers-10-00298]\]

  **USP1**             C527             Preclinical testing using cell lines in combination with MMC and camptothecin            Leukemia                                                                   \[[@B171-cancers-10-00298]\]

  **ATR**              Wortmannin       Preclinical testing using HeLa cell lines in combination with IR or mitomycin C (MMC)    Cervical Cancer                                                            \[[@B172-cancers-10-00298]\]

  **PKA**\             H-9              Preclinical testing using HeLa cell lines in combination with IR                         Cervical Cancer                                                            \[[@B167-cancers-10-00298]\]
  **PKC**\                                                                                                                                                                                                  
  **PKG**                                                                                                                                                                                                   

  **CDK**\             Alsterpaullone   Preclinical testing using HeLa cell lines in combination with IR                         Cervical Cancer                                                            \[[@B167-cancers-10-00298]\]
  **GSK3**                                                                                                                                                                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
